

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 441842000401

Application Number 09/818,344

Applicant

John Richard BAKER

Filing Date March 26, 2001

Group Art Unit ~~1644~~ 1651

Mailing Date July 31, 2001

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
JS	1.	02/22/1983	4,374,829	Harris et al.			
JS	2.	10/18/1983	4,410,541	Kamimae et al.			
JS	3.	07/19/1988	4,758,583	Cerami et al.			
JS	4.	09/12/1989	4,866,090	Hoffman et al.			
JS	5.	08/28/1990	4,952,568	Sawai et al.			
JS	6.	07/07/1992	5,128,360	Cerami et al.			
JS	7.	09/21/1993	5,246,970	Williamson et al.			
JS	8.	12/22/1998	5,852,009	Cerami et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES	NO
JS	9.	09/07/1989	AU 30918/89 A ✓	Australia			Abstract	
JS	10.	05/04/1995	AU 80936/94 A1	Australia				
JS	11.	07/06/1995	AU 14470/95 A	Australia				
JS	12.	05/02/1996	AU 41349/96 A1	Australia				
JS	13.	05/08/1991	EP 0 426 066 A2 ✓	Europe				
JS	14.	11/10/1983	DE 3 217 071 A1 ✓	Germany			Abstract	X
JS	15.	01/27/1988	GB 2 192 789 A ✓	Great Britain				
JS	16.	01/27/1988	GB 2 192 790 A ✓	Great Britain				
JS	17.	09/06/1982	JP 57-144215 A ✓	Japan			Abstract	X
JS	18.	09/24/1987	WO 87/05505 A1 ✓	WIPO				
JS	19.	08/12/1999	WO 99/39712 A1 ✓	WIPO				
JS	20.	04/06/2000	WO 00/18392 A1 ✓	WIPO				
JS	21.	04/06/2000	WO 00/18891 A1 ✓	WIPO				

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

EXAMINER: JS

DATE CONSIDERED: 8/19/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE  
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 441842000401

Application Number 09/818,344

Applicant

John Richard BAKER

Filing Date March 26, 2001

Group Art Unit 1644

Mailing Date July 31, 2001


Examiner Initials	Ref. No.	Title
	22. ✓	American Diabetes Association. (1997). "Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus," <i>Diabetes Care</i> 20:1183-1197.
	23. ✓	American Diabetes Association. (1998). "Economic Consequences of Diabetes Mellitus in the U.S. in 1997," <i>Diabetes Care</i> 21(2):296-309.
	24. ✓	Barthelmebs, M. et al. (1990). "L-Dopa and Streptozotocin-Induced Diabetic Nephropathy in Rats," <i>American Journal of Hypertension</i> 3(6 Part 2):72S-74S.
	25. ✓	Barthelmebs, M. et al. (1991). "Effects of Dopamine Prodrugs and Fenoldopam on Glomerular Hyperfiltration in Streptozotocin-Induced Diabetes in Rats," <i>Journal of Cardiovascular Pharmacology</i> 18(2):243-253.
	26. ✓	Barthelmebs, M. et al. (1995). "Pathophysiological Role of Dopamine in the Kidney: Effects in Diabetes Mellitus and after Contralateral Nephrectomy," <i>Hypertens. Res.</i> 18(Suppl. I):S131-S136.
	27. ✓	Baynes, J.W. (1991). "Role of Oxidative Stress in Development of Complications in Diabetes," <i>Diabetes</i> 40:405-412.
	28. ✓	Boiadzhieva, N. (1990). "The Effect of Dopaminergic Pharmacological Agents on the Pancreatic Islet Apparatus in Rats," <i>Eksp. Med. Morfol.</i> 29(3):20-26. (English abstract)
	29. ✓	Borgstrom, L. et al. (1986). "Pharmacokinetics of N-Acetylcysteine in Man," <i>Eur. J. Clin. Pharmacol.</i> 31:217-222.
	30. ✓	Chan, P.C. and Bielski, B.H.J. (1974). "Enzyme-catalyzed Free Radical Reactions with Nicotinamide Adenine Nucleotides," <i>J. Biol. Chem.</i> 249(4):1317-1319.
	31. ✓	Chan, P.C. and Bielski, B.H.J. (1980). "Glyceraldehyde-3-Phosphate Dehydrogenase-catalyzed Chain Oxidation of Reduced Nicotinamide Adenine Dinucleotide by Perhydroxyl Radicals," <i>J. Biol. Chem.</i> 255(3):874-876.
	32. ✓	Chaturvedi, N. et al. (1998). "Effect of Lisinopril on Progression of Retinopathy in Normotensive People with Type 1 Diabetes," <i>The Lancet</i> 351:28-31.
	33. ✓	Deckert T. et al. (1978). "Prognosis of Diabetics with Diabetes Onset before the Age of Thirtyone," <i>Diabetologia</i> 14:363-370.
	34. ✓	Dubois, R.S. et al. (1970). "Triethylene Tetramine Dihydrochloride in Wilson's Disease," <i>Lancet</i> 2(7676):775.
	35. ✓	Duchin, K.L. et al. (1988). "Pharmacokinetics of Captopril in Healthy Subjects and in Patients with Cardiovascular Diseases," <i>Clin. Pharmacokinetics</i> 14:241-259.
	36. ✓	Elstner, E.F. and Heupel, A. (1976). "Inhibition of Nitrite Formation from Hydroxylammonium-chloride: A Simple Assay for Superoxide Dismutase," <i>Anal. Biochem.</i> 70:616-620.
	37. ✓	Epstein, O. and Sherlock, S. (1980). "Triethylene Tetramine Dihydrochloride Toxicity in Primary Biliary Cirrhosis," <i>Gastroenterology</i> 78(6):1442-1445.

EXAMINER:

DATE CONSIDERED:


5/19/03


EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION</b> IN AN APPLICATION (Use several sheets if necessary)	Docket Number 441842000401	Application Number 09/818,344
	Applicant John Richard BAKER	
	Filing Date March 26, 2001	Group Art Unit 1644
	Mailing Date July 31, 2001	

38.	Executive Committee of the International Union of Biochemistry, ed. (1979). <u>Enzyme Nomenclature, Recommendations of the Nomenclature Committee of the International Union of Biochemistry</u> , Academic Press: London, pp. 19-22. (Table of Contents)
39.	Gennaro, A.R. ed. (1990). <u>Remington's Pharmaceutical Sciences</u> . 18th edition. Mack Publishing Company: Easton, Pennsylvania, 5 pages.(Table of Contents)
40.	Gerhardinger, C. et al. (1995). "Novel Degradation Pathway of Glycated Amino Acids into Free Fructosamine by a <i>Pseudomonas</i> sp. Soil Strain Extract," <i>J. Biol. Chem.</i> 270(1):218-224.
41.	Greenstock, C.L. and Ruddock, G.W. (1976). "Determination of Superoxide ( $O_2^-$ ) Radical Anion Reaction Rates Using Pulse Radiolysis," <i>Int. J. Radiat. Phys. Chem.</i> 8:367-369.
42.	Halliwell, B. (1976). "An Attempt to Demonstrate a Reaction between Superoxide and Hydrogen Peroxide," <i>FEBS Lett.</i> 72(1):8-10.
43.	Halliwell, B. and Gutteridge, J.M.C. (1989). "The Superoxide Theory of Oxygen Toxicity," in <u>Free Radicals in Biology and Medicine</u> . Clarendon Press: Oxford, pp. 136-176.
44.	Haslam, R.H. et al. (1980). "Treatment of Wilson's Disease with Triethylene Tetramine Dihydrochloride," <i>Dev. Pharmacol. Ther.</i> 1(5):318-324.
45.	Holdiness M.R. (1991). "Clinical Pharmacokinetics of N-Acetylcysteine," <i>Clin. Pharmacokinet.</i> 20(2):123-134.
46.	Horiuchi, T. et al. (1989). "Purification and Properties of Fructosyl-amino Acid Oxidase from <i>Corynebacterium</i> sp. 2-4-1," <i>Agric. Biol. Chem.</i> 53(1):103-110.
47.	Ido, Y. et al. (1996). "Interactions between the Sorbitol Pathway, Non-enzymatic Glycation, and Diabetic Vascular Dysfunction," <i>Nephrol. Dial. Transplant.</i> 11(Suppl 5):72-75.
48.	Karlsson, K. and Marklund, S.L. (1987). "Heparin-induced Release of Extracellular Superoxide Dismutase to Human Blood Plasma," <i>Biochem. J.</i> 242:55-59.
49.	Kashihara, N. et al. (1992). "Selective Decreased <i>de novo</i> Synthesis of Glomerular Proteoglycans under the Influence of Reactive Oxygen Species," <i>Proc. Natl. Acad. Sci. USA</i> 89:6309-6313.
50.	Klein, R. et al. (1985). "Retinopathy in Young-Onset Diabetic Patients," <i>Diabetes Care</i> 8(4):311-315.
51.	Kodama, H. et al. (1997). "Metabolism of Administered Triethylene Tetramine Dihydrochloride in Humans," <i>Life Sci.</i> 61(9):899-907.
52.	Marklund, S.L. et al. (1982). "Superoxide Dismutase in Extracellular Fluids," <i>Clin. Chimica Acta</i> 126:41-51.
53.	Mattock, M.B. et al. (1998). "Microalbuminuria and Coronary Heart Disease in NIDDM: An Incidence Study," <i>Diabetes</i> 47:1786-1792.
54.	McCord, J.M. and Fridovich, I. (1969). "Superoxide Dismutase: An Enzymic Function for Erythrocyte (Hemocytin)," <i>J. Biol. Chem.</i> 244(22):6049-6055.
55.	Misra, H.P. and Fridovich, I. (1972). "The Role of Superoxide Anion in the Autoxidation of Epinephrine and a Simple Assay for Superoxide Dismutase," <i>J. Biol. Chem.</i> 247(10):3170-3175.

EXAMINER: 	DATE CONSIDERED: 5/19/03
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	



Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 441842000401

Application Number 09/818,344

Applicant

John Richard BAKER

Filing Date March 26, 2001

Group Art Unit 1644

Mailing Date July 31, 2001


- |     |   |
|-----|---|
| 56. | Misra, H.P. and Fridovich, I. (1977). "Superoxide Dismutase: 'Positive' Spectrophotometric Assays," <i>Anal. Biochem.</i> 79:553-560.   |
| 57. | Mizobuchi, N. et al. (1993). "Serum Superoxide Dismutase (SOD) Activity in Diabetes Mellitus," <i>Rinsho Byori</i> 41:673-678. (English abstract)   |
| 58. | Mogensen, C.E. and Christensen, C.K. (1984). "Predicting Diabetic Nephropathy in Insulin-dependent Patients," <i>New. Eng. J. Med.</i> 311(2):89-93.  |
| 59. | Mogensen, C.E. et al. (1992). "Microalbuminuria in Non-Insulin-Dependent Diabetes," <i>Clin. Nephrol.</i> 38 (suppl 1):S28-S38.   |
| 60. | Morpurgo, L. et al. (1990). "The Role of Copper in Bovine Serum Amine Oxidase," <i>Biol. Metals</i> 3:114-117.  |
| 61. | Obach, R. et al. (1984). "The Pharmacokinetic Profile of Carbidopa in Dogs," <i>J. Pharm. Pharmacol.</i> 36:415-416.  |
| 62. | Palcic, M.M. and Janes, S.M. (1995). "Spectrophotometric Detection of Topa Quinone," <i>Meth. Enzymol.</i> 258:34-38.   |
| 63. | Pappert, E.J. et al. (1997). "The Stability of Carbidopa in Solution," <i>Movement Disorders</i> 12(4):608-623.   |
| 64. | Picard, S. et al. (1996). "Minimally Oxidised LDL as Estimated by a New Method Increase in Plasma of Type 2 Diabetic Patients with Atherosclerosis of Nephropathy," <i>Diabetes and Metabolism</i> 22(1):25-30.   |
| 65. | Robbins, S.L. et al. (1984). "The Kidney," in <u>Pathologic Basis of Disease</u> . 3 <sup>rd</sup> ed., W.B. Saunders Company: Philadelphia, pp. 991-1061.  |
| 66. | Saeki, H. et al. (1998). "Malignant Syndrome Associated with Disseminated Intravascular Coagulation and a High Level of Amylase in Serum, Followed by Diabetic Coma in an Elderly Patient with Parkinson's Disease during L-Dopa Therapy," <i>Nippon Ronen Igakkai Zasshi</i> 35(2):139-144. (English abstract) |
| 67. | Saxena, A.K. et al. (1996). "Purification and Characterization of a Membrane-bound Deglycating Enzyme (1-Deoxyfructosyl Alkyl Amino Acid Oxidase, EC 1.5.3) from a <i>Pseudomonas</i> sp. Soil Strain," <i>J. Biol. Chem.</i> 271(51):32803-32809.  |
| 68. | Smith, P.R. and Thornalley, P.J. (1992). "Mechanism of the Degradation of Non-Enzymatically Glycated Proteins under Physiological Conditions," <i>Eur. J. Biochem.</i> 210:729-739.   |
| 69. | Smith, S.A. and Pogson, C.I. (1977). "Tryptophan and the Control of Plasma Glucose Concentrations in the Rat," <i>Biochem. J.</i> 168(3):495-506.   |
| 70. | Sone, H. et al. (1996). "Inhibition of Hereditary Hepatitis and Liver Tumor Development in Long-Evans Cinnamon Rats by the Copper-Chelating Agent Trientine Dihydrochloride," <i>Hepatology</i> 23(4):764-770.  |
| 71. | Talseth, T. (1976). "Studies on Hydralazine," <i>Eur. J. Clin. Pharmacol.</i> 10(6):395-401.  |
| 72. | Talseth, T. (1977). "Kinetics of Hydralazine Elimination," <i>Clin. Pharm. Thera.</i> 21(6):715-720.  |

EXAMINER:

DATE CONSIDERED:

5/19/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

Docket Number 441842000401

Application Number 09/818,344

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

John Richard BAKER

Filing Date March 26, 2001

Group Art Unit 1644

Mailing Date July 31, 2001

§	73.	Tanabe, R. et al. (1996). "Uptake Mechanism of Trientine by Rat Intestinal Brush-border Membrane Vesicles," <i>J. Pharm. Pharmacol.</i> 48:517-521.
§	74.	The Diabetes Control and Complications Trial Research Group. (1993). "The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-term Complications in Insulin-dependent Diabetes Mellitus," <i>N. Eng. J. Med.</i> 329(14):977-986.
§	75.	UKPDS Study Organisation. (1998). "Intensive Blood-glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33)," <i>Lancet</i> 352:837-853.
§	76.	Vailly, B. et al. (1990). "Prevention of L-dopa of Early Renal Consequences of Diabetes Induced by Streptozocin in Rats," <i>Arch. Mal Coeur Vaiss.</i> 83(8):1259-1262. (English abstract)
§	77.	Walshe, J.M. (1973). "Copper Chelation in Patients with Wilson's Disease: A Comparison of Penicillamine and Triethylene Tetramine Dihydrochloride," <i>Q J. Med. New Series</i> , XLII(167):441-452.
§	78.	Walshe, J.M. (1982). "Treatment of Wilson's Disease with Trientine (Triethylene Tetramine) Dihydrochloride," <i>Lancet</i> 8273:643-647.
§	79.	Witztum, J.L. (1993). "Role of Oxidised Low Density Lipoprotein in Atherogenesis," <i>Br. Heart J.</i> 69 (Suppl):S12-S18.
§	80.	Wolff, S.P. et al. (1991). "Protein Glycation and Oxidative Stress in Diabetes Mellitus and Ageing," <i>Free Rad. Biol. Med.</i> 10:339-352.
§	81.	Wynn, J.E. et al. (1970). "The Toxicity and Pharmacodynamics of EGTA: Oral Administration to Rats and Comparisons with EDTA," <i>Toxicol. Appl. Pharmacol.</i> 16:807-817.
§	82.	Yücel, D. et al. (1998). "Increased Oxidative Stress in Dilated Cardiomyopathic Heart Failure," <i>Clin. Chem.</i> 44(1):148-154.

EXAMINER:

DATE CONSIDERED:

5/19/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.